MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.43M | -69.73M | -55.22M | -39.94M | -45.61M |
| Total Depreciation and Amortization | 751.00K | 745.00K | 742.00K | 378.00K | 364.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.88M | 3.01M | 1.14M | 1.80M | 670.00K |
| Change in Net Operating Assets | 6.00K | 21.43M | -1.19M | -369.00K | -3.90M |
| Cash from Operations | -58.79M | -44.54M | -54.53M | -38.14M | -48.47M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -35.00K | -176.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.91M | 88.40M | 88.25M | 56.28M | -147.16M |
| Cash from Investing | -29.91M | 88.40M | 88.25M | 56.25M | -147.33M |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 73.02M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 72.40M | 480.00K | 0.00 | 100.00K | 151.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 72.40M | 480.00K | 0.00 | 73.12M | 151.00K |
| Foreign Exchange rate Adjustments | 91.00K | -285.00K | 1.39M | -88.00K | 424.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.22M | 44.06M | 35.12M | 91.14M | -195.23M |